NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder, significantly impacting patients' quality of life. Although extensive research has focused on identifying biomarkers, PD diagnosis still relies heavily on clinical features. Current treatments are primarily symptomatic and fail to halt disease progression. Emerging evidence suggests that abnormal bilirubin (BR) levels correlate with PD severity and motor outcomes, highlighting BR's potential as both a biomarker and a therapeutic target. This review elucidates the dual role of BR in PD pathogenesis-modulating oxidative stress, neuroinflammation, and mitochondrial dysfunction-and discusses novel BR-based therapeutic strategies.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.